Shots:

• The P-III BLAZE-1 study involves assessing Bamlanivimab (700 mg) + Etesevimab (1400 mg) vs PBO in 769 COVID-19 patients aged ≥12yrs. who are at high risk for progressing to severe COVID-19 and/or hospitalization
• The results demonstrated an 87% reduction in hospitalizations and death with significant improvements in 2EPs
• The data support the use of the dose recently authorized FDA’s EUA and EMA’s CHMP positive opinion. The results are consistent with those seen in other data sets from P-I- P-II and P-III trials evaluating these antibodies

 ­ Ref: Lilly | Image: France Info